{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Flannery B"],"funding":["University of Michigan","Kaiser Permanente Washington Research Institute","NCATS NIH HHS","University of Pittsburgh","Marshfield Clinic Research Institute","Baylor Scott and White Healthcare","National Institutes of Health","NCIRD CDC HHS"],"pagination":["1798-1806"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6522684"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["68(11)"],"pubmed_abstract":["<h4>Background</h4>In recent influenza seasons, the effectiveness of inactivated influenza vaccines against circulating A(H3N2) virus has been lower than against A(H1N1)pdm09 and B viruses, even when circulating viruses remained antigenically similar to vaccine components.<h4>Methods</h4>During the 2016-2017 influenza season, vaccine effectiveness (VE) across age groups and vaccine types was examined among outpatients with acute respiratory illness at 5 US sites using a test-negative design that compared the odds of vaccination among reverse transcription polymerase chain reaction-confirmed influenza positives and negatives.<h4>Results</h4>Among 7083 enrollees, 1342 (19%) tested positive for influenza A(H3N2), 648 (9%) were positive for influenza B (including B/Yamagata, n = 577), and 5040 (71%) were influenza negative. Vaccine effectiveness was 40% (95% confidence interval [CI], 32% to 46%) against any influenza virus, 33% (95% CI, 23% to 41%) against influenza A(H3N2) viruses, and 53% (95% CI, 43% to 61%) against influenza B viruses.<h4>Conclusions</h4>The 2016-2017 influenza vaccines provided moderate protection against any influenza among outpatients but were less protective against influenza A(H3N2) viruses than B viruses. Approaches to improving effectiveness against A(H3N2) viruses are needed."],"journal":["Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"],"pubmed_title":["Influenza Vaccine Effectiveness in the United States During the 2016-2017 Season."],"pmcid":["PMC6522684"],"funding_grant_id":["U01 IP001039","U01 IP001037","U01 IP001038","U01 IP001035","U01 IP001034","1U01 IP001034","1U01 IP001035","1U01 IP001038","UL1TR001857","1U01 IP001039","UL1 TR001857","1U01 IP001037"],"pubmed_authors":["Jackson LA","Chung JR","Murthy K","McLean HQ","Zimmerman RK","Martin ET","Gaglani M","Rolfes MA","Fry AM","Jackson ML","Belongia EA","Monto AS","Nowalk MP","US Flu VE Investigators","Spencer S","Flannery B"],"additional_accession":[]},"is_claimable":false,"name":"Influenza Vaccine Effectiveness in the United States During the 2016-2017 Season.","description":"<h4>Background</h4>In recent influenza seasons, the effectiveness of inactivated influenza vaccines against circulating A(H3N2) virus has been lower than against A(H1N1)pdm09 and B viruses, even when circulating viruses remained antigenically similar to vaccine components.<h4>Methods</h4>During the 2016-2017 influenza season, vaccine effectiveness (VE) across age groups and vaccine types was examined among outpatients with acute respiratory illness at 5 US sites using a test-negative design that compared the odds of vaccination among reverse transcription polymerase chain reaction-confirmed influenza positives and negatives.<h4>Results</h4>Among 7083 enrollees, 1342 (19%) tested positive for influenza A(H3N2), 648 (9%) were positive for influenza B (including B/Yamagata, n = 577), and 5040 (71%) were influenza negative. Vaccine effectiveness was 40% (95% confidence interval [CI], 32% to 46%) against any influenza virus, 33% (95% CI, 23% to 41%) against influenza A(H3N2) viruses, and 53% (95% CI, 43% to 61%) against influenza B viruses.<h4>Conclusions</h4>The 2016-2017 influenza vaccines provided moderate protection against any influenza among outpatients but were less protective against influenza A(H3N2) viruses than B viruses. Approaches to improving effectiveness against A(H3N2) viruses are needed.","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 May","modification":"2025-04-04T18:36:38.416Z","creation":"2019-09-14T07:03:00Z"},"accession":"S-EPMC6522684","cross_references":{"pubmed":["30204854"],"doi":["10.1093/cid/ciy775"]}}